Latest news with #GMP-ready
Yahoo
6 days ago
- Business
- Yahoo
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
FREMONT, Calif., June 17, 2025--(BUSINESS WIRE)--Celltrio®, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. The new funding will accelerate the global commercialization of RoboCell®, Celltrio's flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities, expand commercial operations across North America, Europe, and Asia and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories. "This investment marks a major milestone for Celltrio and validates our mission to streamline, scale, and standardize cell manufacturing through automation," said Charlie Duncheon, CEO of Celltrio. "We are thrilled to partner with Premier Partners, who share our vision of transforming the future of cell-based therapies with next-generation automation solutions." "We are highly impressed by Celltrio's customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation," said Jay Song, CEO of Premier Partners. "We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide." About Celltrio® Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs. Learn more at About Premier Partners Premier Partners is a leading investment firm specializing in growth equity and growth buyout investments. The firm focuses on rapidly growing sectors, particularly within the healthcare industry, and targets middle-market opportunities globally. Premier Partners has managed approximately $2.9 billion in assets and is supported by an experienced management team with deep industry expertise. Learn more at View source version on Contacts Media Contact: Cathleen LarsonMarketing DirectorBD@
Business Wire
6 days ago
- Business
- Business Wire
Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation
FREMONT, Calif.--(BUSINESS WIRE)--Celltrio®, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell & gene therapy, today announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. Celltrio is redefining cell culturing and cell & gene therapy automation — powered by a $15 million strategic investment Share The new funding will accelerate the global commercialization of RoboCell®, Celltrio's flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities, expand commercial operations across North America, Europe, and Asia and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories. 'This investment marks a major milestone for Celltrio and validates our mission to streamline, scale, and standardize cell manufacturing through automation,' said Charlie Duncheon, CEO of Celltrio. 'We are thrilled to partner with Premier Partners, who share our vision of transforming the future of cell-based therapies with next-generation automation solutions.' 'We are highly impressed by Celltrio's customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation,' said Jay Song, CEO of Premier Partners. 'We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide.' About Celltrio® Celltrio designs and manufactures scalable cell culture automation platforms that integrate seamlessly into R&D and GMP environments. Its flagship RoboCell® system fully automates processes in sterile cell culturing, and cell and gene therapy, delivering high-throughput, consistent results for biopharma, cell therapy, and regenerative medicine labs. Learn more at About Premier Partners Premier Partners is a leading investment firm specializing in growth equity and growth buyout investments. The firm focuses on rapidly growing sectors, particularly within the healthcare industry, and targets middle-market opportunities globally. Premier Partners has managed approximately $2.9 billion in assets and is supported by an experienced management team with deep industry expertise. Learn more at
Yahoo
02-06-2025
- Business
- Yahoo
STEMCELL Technologies Announces Acquisition of Cellular Highways
VANCOUVER, British Columbia & CAMBRIDGE, England, June 02, 2025--(BUSINESS WIRE)--STEMCELL Technologies, Canada's largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile. The acquisition includes the revolutionary Highway1 instrument, which uses Cellular Highways' proprietary VACS™ (Vortex-Actuated Cell Sorting) technology. VACS™ gently and precisely sorts cells and enables high-speed cell sorting in a closed, sterile system through microfluidic vortices. VACS™ uniquely avoids traditional non-sterile droplet-based and electrostatic sorting methods, which can degrade cell health and viability. Highway1 enables researchers and cell therapy developers to process cells more efficiently while maintaining high cell integrity for sensitive applications in research and therapeutic development. This significantly reduces the timelines and costs for research and development. "Since entering the market in 2024, Highway1 has proven to be the fastest GMP-ready cell sorter available and is designed and manufactured under ISO 13485 certification. We are pleased to welcome this powerful instrument, along with the entire Cellular Highways platform, to STEMCELL's portfolio of advanced cell processing instruments," said Dr. Allen Eaves, President and CEO, STEMCELL. "With this new complement to our existing cell isolation and culture product lines, we look forward to further supporting scientists with the tools they need to accelerate innovation in the development of life-changing cell and gene therapies." Current Highway1 customers will receive continued technical support from STEMCELL's dedicated team of Product and Scientific Support specialists. "Cellular Highways customers are in great hands with STEMCELL—a major player in the global biotechnology industry with a stellar reputation for its best-in-class products and customer service," said Dr. Alex Jones on behalf of Cellular Highways. "With STEMCELL's global reach, we are excited that this acquisition will help introduce Highway1 to even more labs around the world." "The acquisition is a testament to Cellular Highways' exceptional team and innovation. With STEMCELL's reputation and global reach, it is ideally positioned to thrive in the rapidly growing research and cell therapy manufacturing markets," said Dr. Sam Hyde, CEO of TTP. "For TTP Group, this demonstrates our unique ability to build and nurture businesses that deliver breakthrough technologies, transform them into market-leading products, and create significant value." "This acquisition aligns with STEMCELL's strategic growth in the cell therapy space," said Dr. Eaves. "With this enhanced ability to support cutting-edge research and biomanufacturing workflows, we will continue to help the scientific community advance research and make discoveries with greater speed and accuracy." About STEMCELL TechnologiesSTEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally. About TTP GroupTTP Group is an independent technology company where scientists and engineers collaborate to invent, design, and engineer breakthrough technologies and products. Working across sectors including healthcare, life sciences, communications, and industrials, TTP combines deep technical expertise with commercial insight to deliver innovations that drive progress and create value. Founded in 1987, TTP Group develops technologies and products for clients worldwide and nurtures high-impact venture businesses. About Cellular HighwaysCellular Highways was founded to take fluorescence-based cell sorting into new therapy development and research applications, requiring fast, gentle, sterile, scalable cell sorting, using the unique potential of the VACS™ technology. Cellular Highways span out from TTP Group. View source version on Contacts Media Contact For more information and to arrange an interview, contact:Ryan-Sang LeeDirector, Corporate Communications, STEMCELL Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
02-06-2025
- Business
- Business Wire
STEMCELL Technologies Announces Acquisition of Cellular Highways
VANCOUVER, British Columbia & CAMBRIDGE, England--(BUSINESS WIRE)--STEMCELL Technologies, Canada's largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile. The acquisition includes the revolutionary Highway1 instrument, which uses Cellular Highways' proprietary VACS™ (Vortex-Actuated Cell Sorting) technology. VACS™ gently and precisely sorts cells and enables high-speed cell sorting in a closed, sterile system through microfluidic vortices. VACS™ uniquely avoids traditional non-sterile droplet-based and electrostatic sorting methods, which can degrade cell health and viability. Highway1 enables researchers and cell therapy developers to process cells more efficiently while maintaining high cell integrity for sensitive applications in research and therapeutic development. This significantly reduces the timelines and costs for research and development. 'Since entering the market in 2024, Highway1 has proven to be the fastest GMP-ready cell sorter available and is designed and manufactured under ISO 13485 certification. We are pleased to welcome this powerful instrument, along with the entire Cellular Highways platform, to STEMCELL's portfolio of advanced cell processing instruments," said Dr. Allen Eaves, President and CEO, STEMCELL. 'With this new complement to our existing cell isolation and culture product lines, we look forward to further supporting scientists with the tools they need to accelerate innovation in the development of life-changing cell and gene therapies.' Current Highway1 customers will receive continued technical support from STEMCELL's dedicated team of Product and Scientific Support specialists. 'Cellular Highways customers are in great hands with STEMCELL—a major player in the global biotechnology industry with a stellar reputation for its best-in-class products and customer service,' said Dr. Alex Jones on behalf of Cellular Highways. 'With STEMCELL's global reach, we are excited that this acquisition will help introduce Highway1 to even more labs around the world.' 'The acquisition is a testament to Cellular Highways' exceptional team and innovation. With STEMCELL's reputation and global reach, it is ideally positioned to thrive in the rapidly growing research and cell therapy manufacturing markets,' said Dr. Sam Hyde, CEO of TTP. 'For TTP Group, this demonstrates our unique ability to build and nurture businesses that deliver breakthrough technologies, transform them into market-leading products, and create significant value.' 'This acquisition aligns with STEMCELL's strategic growth in the cell therapy space,' said Dr. Eaves. 'With this enhanced ability to support cutting-edge research and biomanufacturing workflows, we will continue to help the scientific community advance research and make discoveries with greater speed and accuracy.' About STEMCELL Technologies STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally. About TTP Group TTP Group is an independent technology company where scientists and engineers collaborate to invent, design, and engineer breakthrough technologies and products. Working across sectors including healthcare, life sciences, communications, and industrials, TTP combines deep technical expertise with commercial insight to deliver innovations that drive progress and create value. Founded in 1987, TTP Group develops technologies and products for clients worldwide and nurtures high-impact venture businesses. About Cellular Highways Cellular Highways was founded to take fluorescence-based cell sorting into new therapy development and research applications, requiring fast, gentle, sterile, scalable cell sorting, using the unique potential of the VACS™ technology. Cellular Highways span out from TTP Group.
Business Journals
24-04-2025
- Business
- Business Journals
Eagle Life Science: Elevating Cold Chain Logistics in the Heart of Boston
In a city synonymous with biomedical innovation, logistics excellence is no longer a support function — it's a strategic imperative. That's where Eagle Life Science steps in. As a newly established division of Eagle Air Freight, Eagle Life Science is poised to become Boston's most trusted partner in GDP-certified, GxP-compliant logistics for the life sciences and biotech sectors. Backed by more than three decades of freight forwarding and supply chain experience, Eagle Air Freight has long been a name known for reliability, global reach, and white-glove customer service. Now, that legacy is evolving with a specialized focus on one of the most critical and complex sectors: life sciences. Eagle Life Science was launched to meet the growing demand for precision logistics solutions in Greater Boston's rapidly expanding biopharma ecosystem. From early-stage research labs to commercial manufacturing, life sciences companies need partners who understand the rigor of regulated transport and storage — where the margin for error is zero, and patient impact is real. 'Our clients are developing therapies that save lives. We see ourselves as an extension of their mission,' says Michael O'Brien, President of Eagle Life Science. 'That means having the infrastructure, compliance, and mindset to support them at every step of the journey.' Located in Boston, the division's flagship facility will include a high-capacity cold room, a GMP-ready cleanroom, and a purpose-built freezer farm offering storage at -20°C, 0°C, and +2°C to +8°C — all supported by 24/7 real-time temperature monitoring and GxP-compliant handling protocols. But Eagle Life Science is going beyond storage. By investing in automation, AI-driven risk management, and predictive maintenance, the company aims to deliver unmatched reliability and transparency — essential in a world where every sample, biologic, or investigational drug may represent years of research. Compliance is not an afterthought. It's embedded in the company's DNA. The facility is built to Good Distribution Practice (GDP) standards, with comprehensive GxP training for all staff, digital SOP management, and audit-readiness as a baseline — not a goal. The service offering is designed for flexibility, covering early-phase R&D shipments, clinical trial supply chain support, biologics distribution, and storage for advanced therapies. Whether working with nimble biotech startups or global pharma firms, Eagle Life Science offers scalable, high-touch solutions that adapt to evolving needs. What makes the company different isn't just infrastructure — it's intention. At a time when life sciences supply chains are increasingly complex and global, Eagle Life Science brings a rare combination of agility, specialization, and service that clients say feels more like a partnership than a transaction. As Boston continues to lead in cell and gene therapy, personalized medicine, and biologic innovation, the need for agile, regulatory-savvy logistics partners will only grow. Eagle Life Science is here to meet that need — with purpose, precision, and people who care.
